Boston Scientific Shuffles and Sells in Bid to Right Ship
Executive Summary
Boston Scientific, in a bid to raise capital and focus its efforts, is selling off lower priority businesses as well as its stakes in nearly 100 private and public companies.
You may also be interested in...
Device M&A Poised For A Strong Year
For the first time in five years, large cap, mid cap and financial buyers are all showing a willingness to acquire medical device companies thanks to improving credit markets and strong cash reserves.
Device M&A Poised For A Strong Year
For the first time in five years, large cap, mid cap and financial buyers are all showing a willingness to acquire medical device companies thanks to improving credit markets and strong cash reserves.
Top Device Stories Of 2010: Waiting For The Other Shoes To Fall
For much of the device industry, 2010 felt like a transition year, breeding uncertainty in a number of important areas, including the economy, health care reform, and impending changes to the 510(k) process. A review of the year just ended turns up these stories: Device M&A on the Rebound; Is A First-Mover Advantage Emerging In Medtech? Boston Scientific Is Back In The Game; Early-Stage Deals In Decline; The Future Of Medtech: Where Private Investment Dollars Are Flowing; Transcatheter Valves Take Center Stage; Spine's Downturn; Diabetes Assumptions Begin To Shift; A Landmark Year In Ophthalmology; Health Reform In 2010: A Beginning, Not An End; Changes At FDA: 510(k) Reform Takes Shape, and finally, Is Physician Choice In Product Selection In Danger?